GO:0006161 deoxyguanosine catabolic process: Nucleoside Breakdown, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006161 deoxyguanosine catabolic process describes the biochemical breakdown of deoxyguanosine into guanine and deoxyribose, a key step in nucleoside salvage and purine homeostasis.
• This process is essential for recycling deoxyribose and guanine, and its dysregulation is linked to oxidative stress and disease.
• Key enzymes include purine nucleoside phosphorylase (PNP) and deoxyribose-phosphate aldolase (DERA), which catalyze the phosphorolysis and aldol cleavage steps.
• Defects in deoxyguanosine catabolism can cause immunodeficiency and neurological disorders due to toxic metabolite accumulation.
• CRISPR knockout, knock-in, and point mutation models are powerful tools to dissect the genetic basis of deoxyguanosine catabolic pathway.
• EDITGENE provides comprehensive CRISPR services to study deoxyguanosine catabolic process-related genes in various disease contexts.
Description
The deoxyguanosine catabolic process (GO:0006161) is a fundamental biochemical pathway responsible for the breakdown of deoxyguanosine, a deoxynucleoside composed of guanine and deoxyribose. This process is crucial for maintaining cellular nucleotide pools and preventing the accumulation of toxic intermediates. It plays a central role in purine salvage and recycling, ensuring a balanced supply of deoxyribonucleotides for DNA synthesis and repair. Researchers study this pathway to understand its implications in oxidative stress, immune function, and neurological health. The catabolism of deoxyguanosine is tightly regulated and involves several enzymes that sequentially convert the nucleoside into its constituent parts. Dysregulation of this process has been associated with various pathological conditions, including immunodeficiency and cardiovascular diseases. Thus, investigating the deoxyguanosine catabolic process is essential for elucidating its role in health and disease.
deoxyguanosine catabolic process At A Glance
| GO ID | GO:0006161 |
|---|---|
| GO term | deoxyguanosine catabolic process |
| Ontology | biological_process |
| Synonym | deoxyguanosine breakdown, deoxyguanosine catabolism, deoxyguanosine degradation |
| Major function | Breakdown of deoxyguanosine into guanine and deoxyribose |
| Key enzymes | Purine nucleoside phosphorylase (PNP), deoxyribose-phosphate aldolase (DERA) |
| Pathway | Purine metabolism, nucleoside salvage |
| Related diseases | Immunodeficiency, cardiovascular disease, oxidative stress-related disorders |
What Is GO:0006161?
The deoxyguanosine catabolic process (GO:0006161) refers to the series of chemical reactions that result in the breakdown of deoxyguanosine into guanine and deoxyribose, which can be further metabolized. This process is a key part of purine metabolism and nucleoside salvage pathways.
Why Is deoxyguanosine catabolic process Important in Cell Biology?
Understanding the deoxyguanosine catabolic process is critical because it maintains the balance of deoxyribonucleotides and prevents the accumulation of toxic metabolites that can cause cellular damage. This pathway is also a source of reactive oxygen species and is implicated in oxidative stress, a hallmark of many diseases including cancer and neurodegeneration. Moreover, defects in this pathway can lead to severe immunodeficiency, highlighting its importance in immune function.
• Maintains cellular deoxyribonucleotide pools for DNA synthesis and repair.
• Prevents accumulation of toxic deoxyguanosine metabolites that can cause cell death.
• Plays a role in oxidative stress and antioxidant defense mechanisms.
• Defects are linked to immunodeficiency and neurological disorders.
• Involved in cardiovascular disease pathogenesis through oxidative damage.
• Provides targets for therapeutic intervention in cancer and immune disorders.
• Essential for purine salvage and recycling, conserving cellular energy.
• Its dysregulation is associated with depression and mood disorders.
• Key for understanding space flight-induced oxidative stress.
• Serves as a model pathway for studying nucleoside catabolism.
What Happens During deoxyguanosine catabolic process?
Phosphorolysis of deoxyguanosine
In simple terms: The first step breaks deoxyguanosine into guanine and a sugar-phosphate.
Deoxyguanosine is cleaved by purine nucleoside phosphorylase (PNP) in the presence of inorganic phosphate to yield guanine and deoxyribose-1-phosphate. This reaction is reversible and crucial for the salvage of purine bases.
Isomerization of deoxyribose-1-phosphate
In simple terms: The sugar-phosphate is converted to another form to enter further metabolism.
Deoxyribose-1-phosphate is isomerized to deoxyribose-5-phosphate by phosphopentomutase, preparing it for subsequent steps in the pentose phosphate pathway.
Aldol cleavage of deoxyribose-5-phosphate
In simple terms: The sugar-phosphate is split into smaller molecules.
Deoxyribose-phosphate aldolase (DERA) catalyzes the reversible cleavage of deoxyribose-5-phosphate into glyceraldehyde-3-phosphate and acetaldehyde. This step links deoxyguanosine catabolism to glycolysis and other metabolic pathways.
Fate of guanine
In simple terms: The guanine base is either recycled or further degraded.
Guanine can be salvaged by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) to form GMP, or it can be deaminated to xanthine and further oxidized to uric acid. This branching point is critical for nucleotide homeostasis.
Regulation by substrate availability
In simple terms: The pathway is controlled by the amount of deoxyguanosine available.
The activity of PNP and DERA is regulated by substrate availability and feedback inhibition by downstream metabolites. Oxidative stress can increase deoxyguanosine levels, thereby upregulating the catabolic flux.
Key Genes Involved in GO:0006161 deoxyguanosine catabolic process
The following genes encode enzymes and transporters directly involved in the deoxyguanosine catabolic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PNP | Catalyzes phosphorolysis of deoxyguanosine to guanine and deoxyribose-1-phosphate | Deficiency causes immunodeficiency; target for leukemia therapy |
| DERA | Cleaves deoxyribose-5-phosphate into glyceraldehyde-3-phosphate and acetaldehyde | Potential target for antiviral and anticancer drugs |
| HGPRT | Salvages guanine to GMP | Deficiency leads to Lesch-Nyhan syndrome |
| ADA | Adenosine deaminase, involved in purine metabolism | Deficiency causes SCID |
| GDA | Guanine deaminase, converts guanine to xanthine | Role in purine catabolism and oxidative stress |
| XDH | Xanthine dehydrogenase, oxidizes xanthine to uric acid | Involved in gout and oxidative stress |
| NT5C | Nucleotidase, dephosphorylates nucleotides | Regulates nucleoside levels |
| SLC29A1 | Equilibrative nucleoside transporter 1 | Uptake of deoxyguanosine |
| SLC28A1 | Concentrative nucleoside transporter 1 | Transport of nucleosides |
| DCK | Deoxycytidine kinase, phosphorylates deoxyguanosine | Activation of nucleoside analogs |
| TK1 | Thymidine kinase 1, salvage of thymidine | Cell proliferation marker |
| RRM1 | Ribonucleotide reductase, synthesizes deoxyribonucleotides | Target for cancer therapy |
| RRM2 | Ribonucleotide reductase subunit | Regulates dNTP pools |
| NME1 | Nucleoside diphosphate kinase | Metastasis suppressor |
| NME2 | Nucleoside diphosphate kinase | Regulates GTP levels |
| PRPS1 | Phosphoribosyl pyrophosphate synthetase | Purine synthesis |
| ATIC | AICAR transformylase/IMP cyclohydrolase | Purine biosynthesis |
| GART | Glycinamide ribonucleotide transformylase | Purine synthesis |
How Is deoxyguanosine catabolic process Regulated?
The deoxyguanosine catabolic process is regulated at multiple levels. Enzyme expression is controlled by transcription factors responsive to oxidative stress, such as NRF2. Additionally, feedback inhibition by guanine nucleotides modulates PNP activity. Post-translational modifications, including phosphorylation, can alter enzyme activity. The pathway is also influenced by substrate availability, which is affected by DNA turnover and nucleoside transporters.
deoxyguanosine catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PNP | Immunodeficiency (SCID) | PNP knockout mice, patient-derived iPSCs |
| DERA | Cancer, viral infections | DERA knockout cell lines, xenograft models |
| HGPRT | Lesch-Nyhan syndrome | HGPRT knockout mice, neuronal cell models |
| XDH | Gout, cardiovascular disease | XDH knockout mice, hyperuricemia models |
| ADA | Severe combined immunodeficiency | ADA knockout mice, gene therapy models |
Immunodeficiency
Mutations in PNP cause purine nucleoside phosphorylase deficiency, leading to accumulation of deoxyguanosine and its phosphorylated forms, which are toxic to lymphocytes. This results in severe combined immunodeficiency (SCID) characterized by T-cell deficiency.
Cardiovascular disease
Oxidative stress increases deoxyguanosine oxidation to 8-hydroxy-2'-deoxyguanosine (8-OHdG), a biomarker of DNA damage associated with cardiovascular disease. Elevated 8-OHdG levels correlate with atherosclerosis and hypertension.
Neurological disorders
Impaired deoxyguanosine catabolism can lead to neurotoxicity due to accumulation of guanine derivatives. Oxidative stress and mitochondrial dysfunction in neurons are linked to depression and neurodegenerative diseases.
Cancer
Altered deoxyguanosine catabolism affects dNTP pools and DNA repair, contributing to genomic instability in cancer. Targeting PNP and DERA is explored for anticancer therapy.
From deoxyguanosine catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PNP loss cause immunodeficiency? | PNP knockout mouse model |
| Can DERA inhibition reduce cancer growth? | DERA knockout cancer cell lines |
| What is the role of deoxyguanosine in oxidative stress? | Point mutation in PNP to alter activity |
| How does deoxyguanosine affect neuronal function? | Knock-in of human PNP mutations in mice |
| Can we track deoxyguanosine catabolism in live cells? | Tagged knock-in of PNP with fluorescent protein |
| Does overexpression of DERA protect against oxidative damage? | Overexpression of DERA in cell lines |
How to Study the deoxyguanosine catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Quantification of deoxyguanosine and metabolites | Pathway flux analysis |
| PNP activity assay | Enzyme kinetics | Inhibitor screening |
| DERA activity assay | Enzyme kinetics | Drug discovery |
| CRISPR knockout screen | Gene essentiality | Identify novel pathway regulators |
| 8-OHdG ELISA | Oxidative DNA damage | Biomarker in cardiovascular disease |
| RNA-seq | Gene expression changes | Transcriptional regulation |
| Western blot | Protein expression levels | Validate knockout/overexpression |
Metabolomics
Metabolomic profiling using mass spectrometry can quantify deoxyguanosine and its catabolic intermediates in cells and tissues. This method reveals flux through the pathway under different conditions.
Enzyme activity assays
In vitro assays measure PNP and DERA activity using specific substrates and detect product formation spectrophotometrically. These assays are used to screen inhibitors.
CRISPR screening
Genome-wide CRISPR knockout screens can identify genes essential for deoxyguanosine catabolism and resistance to toxic nucleosides. This approach uncovers novel regulators.
Oxidative stress biomarkers
Levels of 8-OHdG, a product of deoxyguanosine oxidation, are measured by ELISA or HPLC to assess oxidative DNA damage. This biomarker is used in clinical studies.
How CRISPR Can Be Used to Study GO:0006161 deoxyguanosine catabolic process
Knockout
CRISPR knockout of PNP or DERA in cell lines abolishes deoxyguanosine catabolism, leading to accumulation of deoxyguanosine and its phosphorylated derivatives. These models are used to study the consequences of enzyme deficiency and to test rescue strategies.
Point Mutation
Introducing point mutations in PNP that mimic human disease alleles allows researchers to study the molecular basis of immunodeficiency. Such models help dissect the impact of specific amino acid changes on enzyme activity and stability.
Knock-in
Knock-in of human PNP or DERA variants into mouse models enables in vivo studies of deoxyguanosine catabolism in a physiological context. These models are valuable for testing therapeutic interventions.
Overexpression
Overexpression of DERA or PNP in cell lines can enhance deoxyguanosine catabolism and protect against oxidative stress-induced damage. This approach is used to study the protective role of the pathway.
How EDITGENE Supports deoxyguanosine catabolic process Research
Researchers studying deoxyguanosine catabolic process-related genes often need to determine whether a candidate gene is causally involved in the pathway or in disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell and animal models, enabling functional validation of genes such as PNP, DERA, and HGPRT.
Contact EDITGENE today to design your custom CRISPR model for deoxyguanosine catabolic process research.
Frequently Asked Questions About deoxyguanosine catabolic process
What is deoxyguanosine catabolic process?
Deoxyguanosine catabolic process (GO:0006161) is the breakdown of deoxyguanosine into guanine and deoxyribose, which can be further metabolized.
What genes are involved in deoxyguanosine catabolic process?
Key genes include PNP, DERA, HGPRT, and XDH, which encode enzymes that catalyze the steps of the pathway.
How is deoxyguanosine catabolic process regulated?
It is regulated by substrate availability, feedback inhibition by nucleotides, and transcriptional control via oxidative stress-responsive factors.
What diseases are associated with deoxyguanosine catabolic process?
Defects in this pathway are linked to immunodeficiency, cardiovascular disease, and neurological disorders.
What is the role of PNP in deoxyguanosine catabolic process?
PNP catalyzes the phosphorolysis of deoxyguanosine to guanine and deoxyribose-1-phosphate, a critical step in the pathway.
How can I study deoxyguanosine catabolic process using CRISPR?
CRISPR knockout, knock-in, and point mutation models can be used to dissect gene function and disease mechanisms.
What is 8-OHdG and how does it relate to deoxyguanosine catabolic process?
8-OHdG is an oxidized form of deoxyguanosine and a biomarker of oxidative DNA damage, often measured to assess oxidative stress.
Can deoxyguanosine catabolic process be targeted for cancer therapy?
Yes, inhibitors of PNP and DERA are being explored as anticancer agents due to their role in nucleotide metabolism.
What model organisms are used to study deoxyguanosine catabolic process?
Mouse models with PNP or DERA knockout are commonly used, as well as cell lines and patient-derived cells.
How does oxidative stress affect deoxyguanosine catabolic process?
Oxidative stress can increase deoxyguanosine oxidation and alter enzyme activity, impacting pathway flux.
Conclusion
The deoxyguanosine catabolic process (GO:0006161) is a vital metabolic pathway with significant implications for human health and disease. Understanding its regulation and role in conditions such as immunodeficiency, cardiovascular disease, and cancer is essential for developing targeted therapies. Advances in CRISPR technology and metabolomics provide powerful tools to dissect this pathway and identify novel therapeutic targets.
References
- 1. Cheah IK et al.. 2017. Administration of Pure Ergothioneine to Healthy Human Subjects: Uptake, Metabolism, and Effects on Biomarkers of Oxidative Damage and Inflammation.. Antioxid Redox Signal 26(5):193-206 PMID: 27488221
- 2. Toyokuni S et al.. 1995. Persistent oxidative stress in cancer.. FEBS Lett 358(1):1-3 PMID: 7821417
- 3. Stein TP et al.. 2002. Space flight and oxidative stress.. Nutrition 18(10):867-71 PMID: 12361781
- 4. Kroese LJ et al.. 2014. 8-hydroxy-2'-deoxyguanosine and cardiovascular disease: a systematic review.. Curr Atheroscler Rep 16(11):452 PMID: 25252787
- 5. Chapple IL et al.. 2017. Antioxidant Micronutrients and Oxidative Stress Biomarkers.. Methods Mol Biol 1537:61-77 PMID: 27924588
- 8. Black CN et al.. 2015. Is depression associated with increased oxidative stress? A systematic review and meta-analysis.. Psychoneuroendocrinology 51:164-75 PMID: 25462890
